PATENT CLAIM ANALYSIS

Application Number: 16124575
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.

Claim (Index 28):
A bi-specific antibody reagent comprising\n a) an inhibitor of CHI3L1, an inhibitor of Sema7A, an inhibitor of \u03b21-integrin, or an agonist of PlexinC1; and b) an inhibitor of an immune checkpoint protein.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 97.0
- Lexical Diversity: 1.52381
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16124558', '15649373', '15094674', '15649235', '14610837']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6945734458255716
- 35 USC 102 Novelty (BERT): 0.568219948898466
- Combined Prediction Score: 0.681938096132861
- Mean Citation Score: 367.36302
- Max Citation Score: 473.95996
- Similarity Product: 337.6961211973333

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test